These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 2510726)

  • 1. The effect of ponalrestat on sorbitol levels in the lens of obese and diabetic mice.
    Vicario PP; Slater EE; Saperstein R
    Biochem Int; 1989 Sep; 19(3):553-61. PubMed ID: 2510726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonosmotic diabetic cataracts.
    Malone JI; Lowitt S; Cook WR
    Pediatr Res; 1990 Mar; 27(3):293-6. PubMed ID: 2138728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of instillation of aldose reductase inhibitor FR74366 on diabetic cataract.
    Ao S; Kikuchi C; Ono T; Notsu Y
    Invest Ophthalmol Vis Sci; 1991 Nov; 32(12):3078-83. PubMed ID: 1834606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AL-1576, an aldose reductase inhibitor (ARI), did not prevent the decrease of norepinephrine turnover in diabetic rats.
    Yen TT; Fuller RW; Broderick CL; Hemrick-Luecke SK; Perry KW
    Res Commun Chem Pathol Pharmacol; 1988 Aug; 61(2):257-60. PubMed ID: 3141993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitory effects of Ganoderma applanatum on rat lens aldose reductase and sorbitol accumulation in streptozotocin-induced diabetic rat tissues.
    Jung SH; Lee YS; Shim SH; Lee S; Shin KH; Kim JS; Kim YS; Kang SS
    Phytother Res; 2005 Jun; 19(6):477-80. PubMed ID: 16114079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunoreactive C-peptide in spontaneous syndromes of obesity and diabetes in mice.
    Flatt PR; Bailey CJ; Hampton SM; Swanston-Flatt SK; Marks V
    Horm Metab Res; 1987 Jan; 19(1):1-5. PubMed ID: 3549500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of insulin on aldose reductase activity in the lens of rats with streptozotocin-induced diabetes].
    Nishigami T
    Nippon Ganka Gakkai Zasshi; 1990 Feb; 94(2):128-34. PubMed ID: 2114733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altering the course of cataracts in diabetic rats.
    Fukushi S; Merola LO; Kinoshita JH
    Invest Ophthalmol Vis Sci; 1980 Mar; 19(3):313-5. PubMed ID: 6766909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fast anterograde axonal transport in wasted and non-wasted diabetic rats; effects of aldose reductase inhibition.
    Whiteley SJ; Townsend J; Tomlinson DR; Willars GB
    Diabetes Res; 1986 Nov; 3(9):447-52. PubMed ID: 2435444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of lens aldose reductase activity by nitric oxide.
    Srivastava S; Tammali R; Chandra D; Greer DA; Ramana KV; Bhatnagar A; Srivastava SK
    Exp Eye Res; 2005 Dec; 81(6):664-72. PubMed ID: 15967436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative importance of aldose reductase versus nonenzymatic glycosylation on sugar cataract formation in diabetic rats.
    Kador PF; Lee JW; Fujisawa S; Blessing K; Lou MF
    J Ocul Pharmacol Ther; 2000 Apr; 16(2):149-60. PubMed ID: 10803425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diabetic complications in lens and nerve and their prevention by sulindac or sorbinil: two novel aldose reductase inhibitors.
    Jacobson M; Sharma YR; Cotlier E; Hollander JD
    Invest Ophthalmol Vis Sci; 1983 Oct; 24(10):1426-9. PubMed ID: 6413448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of sorbitol dehydrogenase inhibition on sugar cataract formation in galactose-fed and diabetic rats.
    Kador PF; Inoue J; Secchi EF; Lizak MJ; Rodriguez L; Mori K; Greentree W; Blessing K; Lackner PA; Sato S
    Exp Eye Res; 1998 Aug; 67(2):203-8. PubMed ID: 9733586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isoliquiritigenin: a new aldose reductase inhibitor from glycyrrhizae radix.
    Aida K; Tawata M; Shindo H; Onaya T; Sasaki H; Yamaguchi T; Chin M; Mitsuhashi H
    Planta Med; 1990 Jun; 56(3):254-8. PubMed ID: 2118267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Central leptin gene therapy, a substitute for insulin therapy to ameliorate hyperglycemia and hyperphagia, and promote survival in insulin-deficient diabetic mice.
    Kojima S; Asakawa A; Amitani H; Sakoguchi T; Ueno N; Inui A; Kalra SP
    Peptides; 2009 May; 30(5):962-6. PubMed ID: 19428774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current status of aldose reductase inhibitors.
    Zimmerman BR
    Diabetes Care; 1987; 10(1):123-5. PubMed ID: 3105984
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of a new aldose reductase inhibitor on various tissues in vitro.
    Terashima H; Hama K; Yamamoto R; Tsuboshima M; Kikkawa R; Hatanaka I; Shigeta Y
    J Pharmacol Exp Ther; 1984 Apr; 229(1):226-30. PubMed ID: 6423811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ultrastructural observations on myelinated fibres in experimental diabetes: effect of the aldose reductase inhibitor ponalrestat given alone or in conjunction with insulin therapy.
    Bhoyrul S; Sharma AK; Stribling D; Mirrlees DD; Peterson RG; Farber MO; Thomas PK
    J Neurol Sci; 1988 Jun; 85(2):131-47. PubMed ID: 2968441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of a new aldose reductase inhibitor on diabetic complications in rats.
    Gervasi GB; Bartoli C; Catalani R; Farina C; Carpita G; Caccia G; Ammannati P
    Arzneimittelforschung; 1991 Nov; 41(11):1160-3. PubMed ID: 1810261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Properties of ICI 128,436, a novel aldose reductase inhibitor, and its effects on diabetic complications in the rat.
    Stribling D; Mirrlees DJ; Harrison HE; Earl DC
    Metabolism; 1985 Apr; 34(4):336-44. PubMed ID: 3920474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.